The EPS beat and cost reduction are positive, but the stock's movement will hinge on clinical catalysts, specifically the amended VERSATILE-003 protocol and any FDA feedback on accelerated approval. Monitor the 8:00 am ET investor webcast for updates on trial enrollment restart and regulatory interactions. The $21.7M cash position provides runway into mid-2027 at current burn rate, but dilution risk remains high given the pre-revenue stage.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $1.33entry
- T+1 · 6mo ago +7.52%α +6.74% · $1.43
- T+5 · 6mo ago −24.81%α −23.65% · $1.00
- T+20 · 5mo ago −15.79%α −15.18% · $1.12
- T+60 · 3mo ago −41.71%α −46.14% · $0.7753
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, driven by lower R&D and G&A expenses. The EPS of -$0.13 beat the consensus estimate of -$0.14 by 7.1%, but the company remains a pre-revenue clinical-stage biotech with no approved products and a cash runway of $21.7M. The key catalyst is the amended VERSATILE-003 Phase 3 trial protocol incorporating PFS as an interim endpoint, which could enable an accelerated approval pathway for PDS0101 in head and neck cancer.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $7.3M ($0.13/share) vs $8.5M ($0.21/share) in Q1 2025
- EPS of -$0.13 beat consensus estimate of -$0.14 by 7.1%
- Cash balance of $21.7M as of March 31, 2026, down from $26.7M at year-end 2025
- Amended VERSATILE-003 Phase 3 trial to include PFS as interim primary endpoint, potentially enabling accelerated approval for PDS0101
- Positive mCRC data published in JCO: 77.8% ORR at 6 months and ~85% 24-month survival rate with PDS01ADC combination
- R&D expenses decreased to $3.5M from $5.8M YoY due to lower clinical and manufacturing costs
- Accumulated deficit of $224M; total stockholders' equity of $3.9M
Financial Impact
Q1 2026 net loss improved by $1.2M YoY; cash burn of ~$5M in the quarter; no revenue generated
Risk Factors
- Pre-revenue biotech with no approved products; entirely dependent on clinical trial success
- Cash burn of ~$5M/quarter; $21.7M cash provides limited runway without additional financing
- VERSATILE-003 trial amendment may face FDA pushback on accelerated approval pathway
- High dilution risk: weighted average shares outstanding increased 37% YoY to 55.5M
- Accumulated deficit of $224M with no near-term revenue prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293836 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers